- Home
- RARE
as 03-28-2025 4:00pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 3.6B | IPO Year: | 2014 |
| Target Price: | $95.93 | AVG Volume (30 days): | 736.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.71 - $60.37 | Next Earning Date: | 05-01-2025 |
| Revenue: | $560,230,000 | Revenue Growth: | 29.01% |
| Revenue Growth (this year): | 19.15% | Revenue Growth (next year): | 32.11% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Mar 6 '25 | Sell | $40.40 | 1,785 | $72,114.00 | 106,169 | |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Mar 1 '25 | Sell | $42.10 | 967 | $40,710.70 | 50,265 | |
| Kassberg Thomas Richard | RARE | CBO & EVP | Mar 1 '25 | Sell | $42.10 | 6,028 | $253,778.80 | 265,238 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Mar 1 '25 | Sell | $42.10 | 12,846 | $540,816.60 | 75,287 | |
| Crombez Eric | RARE | EVP and Chief Medical Officer | Mar 1 '25 | Sell | $42.10 | 8,945 | $376,584.50 | 71,922 | |
| Harris Erik | RARE | EVP & Chief Commercial Officer | Mar 1 '25 | Sell | $42.10 | 15,103 | $635,836.30 | 87,855 | |
| KAKKIS EMIL D | RARE | President & CEO | Feb 28 '25 | Sell | $42.29 | 98,434 | $4,153,571.40 | 641,731 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Feb 27 '25 | Sell | $42.84 | 2,990 | $128,223.90 | 75,287 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy
GlobeNewswire
12 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
13 days ago
Ultragenyx price target lowered to $115 from $140 at Piper Sandler
GlobeNewswire
a month ago
Ultragenyx to Participate at Investor Conferences in March
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
a month ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Ultragenyx Pharmaceutical Eyes Aug. 18 FDA Approval for Sanfilippo Syndrome Gene Therapy Treatment
GlobeNewswire
a month ago
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.